

Data Sharing Statement

Choe. Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-Line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *JAMA Netw Open*. Published December 15, 2022. doi:10.1001/jamanetworkopen.2022.45956

Data

Data available: Yes

Data types: Data (not involving human participants)

How to access data: JHC and MA had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Emails:

Mohamed.Abouelenein@med.usc.edu and jhchoe@usc.edu

When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: Researchers whose proposed use of the data has been approved

Types of analyses: Cost-effectiveness analysis

Mechanisms of data availability: After approval of a proposal